Printed medications that are individually tailored to each patient: that is what DiHeSys (Digital Health Systems) stands for. As a partner, Harro Höfliger supports the construction of the pharmaceutical printers required for this.
Medical treatments are most successful when they are tailored precisely to the individual. Factors such as body weight, gender and genetics can influence the effectiveness of medicines. DiHeSys, based in Ulm, has therefore made it its mission to enable tailor-made therapies.
The focus is on the individualized production of printed medicines - always with the exact amount and composition of active ingredients that the patient needs. Together with Harro Höfliger, the company developed the FlexDosePrinter for the production of personalized thin films and tablets.
The pharmaceutical-grade FlexDosePrinter produces personalized thin films and tablets.
When producing the thin films (oral dispersible films), the print heads print a placebo carrier with a clearly defined amount of active ingredient solution. A heating plate inside the FlexDosePrinter then ensures that the solvent evaporates and the active ingredient remains.
The basis of 3D printing is well-tolerated polymer filaments with embedded active ingredients. This material can be used to produce personalized tablets in the FlexDosePrinter. Since only a few excipients are required, drugs with larger amounts of active ingredients can also be produced. Printing in multiple layers makes it possible to combine different active ingredients in one tablet. In addition, an individual release profile can be implemented.
With the FlexDosePrinter, pharmacists and hospital staff could in future produce personalized medications directly at the patient's premises. DiHeSys provides users with comprehensive support: from developing formulations for inks containing active ingredients to providing the printers and supplying cartridges and consumables.
Personalized medications allow patient-specific dosing and the combination of different active ingredients.
Comments